Tear metabolomics for the diagnosis of primary open-angle glaucoma.

Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Botello-Marabotto M
Grupos
Abstract
Primary Open-Angle Glaucoma (POAG) is the most prevalent glaucoma type, and the leading cause of irreversible visual impairment and blindness worldwide. Identification of early POAG biomarkers is of enormous value, as there is not an effective treatment for the glaucomatous optic nerve degeneration (OND). In this pilot study, a metabolomic analysis, by using proton ( 1 H) nuclear magnetic resonance (NMR) spectroscopy was conducted in tears, in order to determine the changes of specific metabolites in the initial glaucoma eyes and to discover potential diagnostic biomarkers. A classification model, based on the metabolomic fingerprint in tears was generated as a non-invasive tool to support the preclinical and clinical POAG diagnosis. 1 H NMR spectra were acquired from 30 tear samples corresponding to the POAG group (n = 11) and the control group (n = 19). Data were analysed by multivariate statistics (partial least squares-discriminant analysis: PLS-DA) to determine a model capable of differentiating between groups. The whole data set was split into calibration (65%)/validation (35%), to test the performance and the ability for glaucoma discrimination. The calculated PLS-DA model showed an area under the curve (AUC) of 1, as well as a sensitivity of 100% and a specificity of 83.3% to distinguish POAG group versus control group tear data. This model included 11 metabolites, potential biomarkers of the disease. When comparing the study groups, a decrease in the tear concentration of phenylalanine, phenylacetate, leucine, n-acetylated compounds, formic acid, and uridine, was found in the POAG group. Moreover, an increase in the tear concentration of taurine, glycine, urea, glucose, and unsaturated fatty acids was observed in the POAG group. These results highlight the potential of tear metabolomics by 1 H NMR spectroscopy as a non-invasive approach to support early POAG diagnosis and in order to prevent visual loss.
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 0039-9140, 1873-3573
- Tipo:
- Article
- Páginas:
- 125826-125826
- Factor de Impacto:
- 0,983 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Talanta ELSEVIER SCIENCE BV
Documentos
- No hay documentos
Filiaciones
Keywords
- (1)H NMR spectroscopy, Biomarkers, Diagnosis, Metabolomics, Primary open angle glaucoma
Proyectos asociados
NANOMATERIALES INTELIGENTES, SONDAS Y DISPOSITIVOS PARA EL DESARROLLO INTEGRADO DE NUEVAS HERRAMIENTAS APLICADAS AL CAMPO BIOMÉDICO
Investigador Principal: JUAN BAUTISTA SALOM SANVALERO
MAT2015-64139-C4-1-R . MINISTERIO DE ECONOMIA Y COMPETITIVIDAD . 2016
OFTARED.
Investigador Principal: MARÍA DOLORES PINAZO DURÁN
RD16/0008/0022 . INSTITUTO DE SALUD CARLOS III . 2017
PROGRAMA TÉCNICO DE APOYO. MODALIDAD INFRAESTRUCTURA.
Investigador Principal: RAMÓN MARTÍNEZ MÁÑEZ
PTA2016-12603-1 . MINISTERIO DE ECONOMIA Y COMPETITIVIDAD . 2018
PLATAFORMA PARA LA DETECCIÓN DE PATÓGENOS BASADA EN MATERIALES CON PUERTAS MOLECULARES (PATH-GATE).
Investigador Principal: RAMÓN MARTÍNEZ MÁÑEZ
DTS18/00090 . INSTITUTO DE SALUD CARLOS III . 2019
Estudio de la inestabilidad de placa de ateroma y riesgo de accidente cerebro-vascular mediante análisis metabolómico por espectroscopía de resonancia magnética nuclear.
Investigador Principal: MANUEL MIRALLES HERNÁNDEZ
PI20/01171 . INSTITUTO DE SALUD CARLOS III . 2021
ENSAYO CLÍNICO EN FASE IV, ABIERTO, ALEATORIZADO, DE 3 BRAZOS, MULTICÉNTRICO Y DE 12 MESES DE DURACIÓN, PARA EVALUAR LA EFICACIA Y SEGURIDAD DE DOS REGÍMENES DE TRATAMIENTO, BIMENSUAL O PRN FLEXIBLE INDIVIDUALIZADO DE "TRATAR Y EXTENDER", VERSUS UN RÉGIME N PRN SEGÚN CRITERIOS DE ESTABILIZACIÓN MEDIANTE EVALUACIONES MENSUALES DE INYECCIONES INTRAVÍTREAS DE RANIBIZUMAB 0,5 MG EN PACIENTES NAIVE CON NEOVASCULARIZACIÓN COROIDEA SECUNDARIA A LA DEGENERACIÓN MACULAR RELACIONADA CON LA EDAD. ESTUDIO IN-EYE.
Investigador Principal: ROBERTO GALLEGO PINAZO
CRFB002AES03T
Detección de patología cardiovascular en sangre con puertas moleculares del microRNA-4732-3p: una herramienta innovadora. (ACRÓNIMO GATE-4732-3p)
Investigador Principal: PILAR SEPÚLVEDA SANCHIS
DTS23/00017 . INSTITUTO DE SALUD CARLOS III . 2024
NUEVOS SISTEMAS DE DIAGNÓSTICO Y TRATAMIENTO BASADOS EN QUÍMICA SUPRAMOLECULAR Y NANOTECNOLOGÍA
Investigador Principal: RAMÓN MARTÍNEZ MÁÑEZ
INVEST/2023/443 . CONSELLERIA DE INNOVACIÓN, UNIVERSIDADES, CIENCIA Y SOCIEDAD DIGITAL . 2023
Cita
Botello M,Martínez MC,Pinazo MD,Martínez R. Tear metabolomics for the diagnosis of primary open-angle glaucoma. Talanta. 2024. 273. p. 125826-125826. IF:5,600. (1).